Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 16;25(9):57.
doi: 10.1007/s11916-021-00977-w.

Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and Toxicity

Eric S Schwenk  1 , Basant Pradhan  2 , Rohit Nalamasu  3 , Lucas Stolle  4 , Irving W Wainer  5 , Michael Cirullo  6 , Alexander Olson  7 , Joseph V Pergolizzi  4 , Marc C Torjman  7 , Eugene R Viscusi  7
Affiliations
Review

Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and Toxicity

Eric S Schwenk et al. Curr Pain Headache Rep. .

Erratum in

Abstract

Purpose of review: While ketamine's analgesia has mostly been attributed to antagonism of N-methyl-D-aspartate receptors, evidence suggests multiple other pathways are involved in its antidepressant and possibly analgesic activity. These mechanisms and ketamine's role in the nociplastic pain paradigm are discussed. Animal studies demonstrating ketamine's neurotoxicity have unclear human translatability and findings from key rodent and human studies are presented.

Recent findings: Ketamine's metabolites, and (2R,6R)-hydroxynorketamine in particular, may play a greater role in its clinical activity than previously believed. The activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and the mammalian target of rapamycin by ketamine are mechanisms that are still being elucidated. Ketamine might work best in nociplastic pain, which involves altered pain processing. While much is known about ketamine, new studies will continue to define its role in clinical medicine. Evidence supporting ketamine's neurotoxicity in humans is lacking and should not impede future ketamine clinical trials.

Keywords: Hydroxynorketamine; Ketamine; NMDA; Neurotoxicity; Nociplastic.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

Papers of particular interest, published recently, have been highlighted as: • Of importance
    1. Laskowski K, Stirling A, McKay WP, Lim HJ. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anaesth. 2011;58(10):911–23. - PubMed - DOI - PMC
    1. Maher DP, Chen L, Mao J. Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization. Anesth Analg. 2017;124(2):661–74. - PubMed - DOI - PMC
    1. Pickering G, Pereira B, Morel V, Corriger A, Giron F, Marcaillou F, et al. Ketamine and magnesium for refractory neuropathic pain: a randomized, double-blind, crossover trial. Anesthesiology. 2020;133(1):154–64. - PubMed - DOI - PMC
    1. Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug Des Devel Ther. 2019;13:3051–67. - PubMed - PMC - DOI
    1. Orhurhu VJ, Roberts JS, Ly N, Cohen SP. Ketamine in acute and chronic pain management. In: StatPearls, edn. eds. Treasure Island: StatPearls Publishing; 2020.

LinkOut - more resources